RemeGen Co

RemeGen Co Financial Leverage

The Financial Leverage (Equity Multiplier) of RemeGen Co (688331.SS) as of Oct 26, 2026 is 3.12. In the previous year, Financial Leverage (Equity Multiplier) was 2.77 — a change of 12.85% (higher).

Financial Leverage

3.12

YoY

12.85%

Last updated:

Financial Leverage (Equity Multiplier) of RemeGen Co is 2025 3.12 . Financial Leverage (Equity Multiplier) of RemeGen Co was 2024 2.77 . It decreases by 12.85% higher compared to the previous year.

The RemeGen Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
-1.07 CNY
Jan 1, 2019
-2.97 CNY
Jan 1, 2020
1.15 CNY
Jan 1, 2021
1.21 CNY
Jan 1, 2022
1.21 CNY
Jan 1, 2023
1.61 CNY
Jan 1, 2024
2.77 CNY
Jan 1, 2025
3.12 CNY
The RemeGen Co Financial Leverage history
YEARFinancial LeverageYoY
3.12+12.85%
2.77+72.13%
1.61+33.03%
1.21+0.18%
1.21+5.35%
1.15-138.55%
-2.97+178.74%
-1.07—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

Financial Leverage (Equity Multiplier) of RemeGen Co is 3.12 in 2025.

Financial Leverage (Equity Multiplier) of RemeGen Co changed from 2.77 to 3.12, representing a 12.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s RemeGen Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — RemeGen Co

All Key Metrics — RemeGen Co